Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

Table 2 Performance matrix of disease progression model

	Predicted Non-progressor	Predicted Progressor	Indeterminate
Observed Non-progressor	23	1	15
Observed Progressor	0	22	5

ISSN: 1479-5876